Hereditary tyrosinemia type 1, due to a deficiency of fumarylacetoacetase (FAH), is characterized by progressive liver damage and renal tubular dysfunction and may occur in an acute or a chronic form. An Ala 134 to Asp (GCT to GAT) transition was found in one Turkish and two Norwegian patients with chronic tyrosinemia. SphI digestion of polymerase chain reaction (PCR) amplified genomic DNA identified the mutation and showed that the patients were heterozygous. All these patients had immunoreactive FAH protein in fibroblasts. Another Norwegian patient with chronic disease, without FAH immunoreactive material in fibroblasts, had a Pro 342 to Leu mutation (CCG to CTG). This mutation was identified by MspI digestion of PCR amplified genomic DNA, and the patient was heterozygous. Northern blotting showed FAH mRNA of normal size and amounts in all patients. Site directed mutagenesis and translation in a rabbit reticulocyte lysate demonstrated that both mutations abolished FAH activity.
Introduction
Hereditary tyrosinemia type 1 (HT1) (McKusick 27670) is an autosomal recessive disorder caused by deficiency of fumarylacetoacetase (FAH) (EC 3.7.1.2), the last enzyme in tyrosine degradation (Goldsmith and Laberge 1989) . The enzyme block leads to accumulation of the alkylating metabolites maleylacetoacetate and fumarylacetoacetate, presumably responsible for the damage found in the disorder. The clinical picture is heterogeneous and is described as acute or chronic. The acute form of the disease results in death during the first year of life due to liver failure. The chronic form presents with childhood rickets and progressive liver disease. Development of hepatocellular carcinoma is frequent in chronic HT1 (Weinberg et Correspondence to: H. Rootwelt, Institute of Clinical Biochemistry, Rikshospitalet, N-0027 Oslo, Norway al. 1976). Dietary treatment with restriction of tyrosine and phenylalanine alleviates the rickets but liver transplantation has so far been the only definite treatment. Recently treatment of HT1 by inhibition of 4-hydroxyphenylpyruvate dioxygenase was reported (Lindstedt et al. 1992) .
Early studies in tyrosinemia patients showed absence of FAH immunoreactivity in acute patients while chronic patients had reduced amounts of immunoreactive material (Berger et al. 1988; Tanguay et al. 1990 ). We found that among chronic patients some had immunoreactive FAH material but the majority were immunonegative, indicating at least two subgroups of chronic HT1 .
Two FAH cDNA clones have been described (Agsteribbe et al. 1990; Phaneuf et al. 1991 ) and the gene for FAH has been mapped to chromosome 15q23-25 . Six different haplotypes have been characterized by restriction fragment length polymorphisms at the FAH locus . A single causal mutation in one patient with acute HT1 has been reported (Phaneuf et al. 1992) .
We now report a common missense mutation in two Norwegian and one Turkish patients. All had immunoreactive FAH material in fibroblasts. A third Norwegian patient was immunonegative for FAH material and had another missense mutation. The mutations were identified by sequencing and by restriction enzyme digestion of polymerase chain reaction (PCR) amplified genomic DNA. The three Norwegian patients have evidence of a mosaic pattern of FAH activity in liver tissue, as recently described for five other Norwegian patients with chronic HT1 (Kvittingen et al. 1993) . In this context, their mutations may be of particular interest.
Materials and methods

Patients
Three Norwegian and one Turkish patient were investigated. The three Norwegian patients has a typical chronic form, presenting with rickets in early school age and surviving to the third decade. Clinical details on these patients have been given previously (Kvittingen et al. 1991 . The Turkish patient had symptoms from 3 months of age and was diagnosed at 10 months with rickets, hepatomegaly and slightly elevated liver tests (Co~kun et al. 1991, case 4) . Presently, at age 5 years, she is in fairly good clinical condition. The three Norwegian patients all had variable FAH activities in liver tissue, from < 2% up to 20%-30% of mean normal level, indicating the presence of the "mosaicism" phenomenon (Kvittingen et al. 1993 ).
Determination of FAH activity and Western blotting
Assay of FAH activity in fibroblasts was performed as reported previously (Kvittingen and Brodtkorb 1986) . Western blotting was performed according to Berger et al. (1987) .
Isolation of a full length human FAH cDNA clone
Human liver cDNAs were synthesized by incubating human liver poly(A) + RNA (5 ~g) for 1 h at 42~ in a reaction mixture (20 ~tl) containing 10 mM HC1, pH 8.3, 50 rnM KC1, 5 mM MgC12, 1 mM dNTPs, 1.6 ~tg poly(T) primer, 50 units of RNasin and 20 units of AMV reverse transcriptase. The phFAH cDNA clone was isolated by PCR amplification (Saiki et al. 1988 ) of this cDNA using two oligonucleotide primers deriving from nucleotides -12 to +9 (5"-GTGCTCTTCAGCATGTCCTTC, sense) and 1392 to 1370 (5"-GCAGGCCTCAGAGCACAATGGC, antisense) of the human FAH cDNA . The sense and antisense primers contain additional XbaI and SacI linkers, respectively, and after digestion with XbaI and SacI, the amplified fragment was subcloned into a pGEM1 vector (Promega Corp., Madison, Wis.). The identity of the phFAH clone was confirmed by sequencing.
Isolation of RNA and Northern blotting
Total RNA was isolated from cultured fibroblasts by an acid guanidinium thiocyanate-phenol-chlorofonn extraction (Chomczynski and Sacchi 1987) , electrophoresed on a 1% formaldehyde agarose gel (Sambrook et al. 1989) , and transferred to GeneScreen Plus nylon membrane (NEN Research Products, Boston, Mass.) by vacuum blotting. Prehybridization in phosphate buffer, 0.245 M, pH 7.2, 7% SDS, 1% BSA and 1 mM EDTA was done for 3 h at 67~ Overnight hybridization at 67~ was in the same buffer with a single stranded probe labeled with [c~32p]dCTP 3,000 Ci/mmol (Amersham, Buckinghamshire, England), using FAH cDNA as template for one-sided PCR with only antisense primer present (Bednarczuk et al. 1991) . The membranes were washed two times for 10 min at room temperature and two times for 20 min at 55~ in 2 x SSC, 1% SDS, and finally twice for 90 min in 0.1 • SSC, 0.1% SDS at 55~ Preflashed Fuji HR-G films were exposed using intensifying screens at -80~ After stripping the membranes were reprobed with chicken [3-actin cDNA (Cleveland et al. 1980) as an internal standard.
cDNA synthesis, PCR and sequencing
Poly(A) mRNA was isolated from lysed fibroblasts by hybridization to paramagnetic poly(T) coated beads (Dynal, Oslo, Norway). cDNA was synthesized using a poly(T) primer and AMV reverse transcriptase (Promega). FAH cDNA from position -56 to + 1371, relative to the translation initiation site in normal FAH cDNA , was amplified by the PCR. The 3" antisense primer was biotinylated for coupling to streptavidin coated paramagnetic particles (Dynabeads M-280, Dynal, Norway) for generating single stranded templates for sequencing (Hultman et al. 1989) . After melting the PCR products in 0.1 M NaOH, the antisense FAH strands coupled to the beads were separated on a magnet (Dynal MPC-E), washed and sequenced by a Sequenase protocol using fluorescent primers (Kristensen et al. 1988 ) on an automatic DNA sequencing instrument constructed at EMBL, Heidelberg, Germany (Ansorge et al. 1987) . The sense DNA in solution was neutralized and sequenced in the opposite direction (Hultman et al. 1991) .
Identification of the mutations by restriction analysis
Phenol-chloroform extracted genomic DNA (1 ~tg) or 10 I-tl lysate (Balnaves et al. 1991 ) from leukocytes or cultured skin fibroblasts was amplified in 100 ~tl 10 mM TRIS-HC1, pH 9.0, 50 mM KC1, 0.1% Triton X-100, 1.75 mM MgCI2, 0.3 mM of each dNTP and 20 pmol of the primer pairs; 5"-GACTTCTATTCCTCTCGGCAG and 5"-CTGAACATGATTCCGACGTTGG for A134D, and 5"-CACTCTGTCAACGGCTGCAAC and 5"-CCCGCTGATGGTC-CCAGAAG for P342L. Taq DNA polymerase, 2.5 units, was added after denaturation for 10 rain at 98~ Amplification was by 35 cycles of 30 s at 94~ and 1 rain at 61~ followed by 3 min final elongation at 72~ The PCR products were digested with SphI (Boehringer, Mannheim) for A134D or Mspl (Promega) for P342L and electrophoresed on 4% NuSieve 1.5% agarose minigels. The allele with the C4~ mutation of A134D remains undigested at 50 bp, whereas the normal sequence gives fragments of 27 and 23 bp. The allele with the C1~ mutation of P342L remains undigested at 63 bp, whereas the normal sequence is cut into 28 and 35 bp fragments.
Mutagenesis and expression analysis
Mutagenesis was performed by the Altered Sites in vitro Mutagenesis System (Promega) and the expression analysis using the TNT Coupled Reticulocyte Lysate System (Promega). Full length ph-FAH cDNA was subcloned into the pALTER-1 vector and the desired mutation was introduced simultaneously with ampicillin resistance repair by the double primer method described in the protocol. Ampicillin resistant clones were screened by sequencing. pALTER-1-FAH with the desired mutations and positive and negative controls were transcribed and translated with [35S] methionine (SJ1015, Amersham) according to the TNT protocol. Microsomal membranes were not included, as no postribosomal modification of FAH is known.
The FAH activity of the translation products was determined by incubating 5 ~tl of the reticulocyte lysate with fumarylacetoacetate (final concentration 23 ~tmol/1) in 440 ~tl phosphate buffer, 90 raM, pH 7.5, recording the decrease of absorbance at 330 nm.
The labeled translation products were visualized after polyacrylamide gel electrophoresis (PAGE) by autoradiography of the dried gel with preflashed Fuji HR-G film.
Results
Northern blot analysis, Fig. 1A , showed that all patients (lanes 1-3 and 5) had FAH mRNA of equal size and comparable amounts with the control in lane 4, when correlated to actin mRNA.
Western blotting, The sequencing data of amplified FAH eDNA in Fig. 2A show the C to A point mutation in nucleotide position 401 from the ATG start codon found in the three patients with FAH cross-reactive material (Fig. 1B, lanes  1-3) . This introduces aspartic acid instead of alanine in amino acid position 134 (A134D). Figure 2B demonstrates the C to T transversion in nucleotide position 1025, replacing proline with leucine in amino acid position 342 (P342L), in the Norwegian patient with no detectable immunoreactive material in fibroblasts (Fig. 1B, lane 5) . There was no distinct double sequencing top at the position of the mutation nor any other mutations in the coding region of the amplified cDNAs to indicate heterozygosity in any of the four patients. However, the A134D mutation removes a restriction site for SphI and the P342L mutation removes a restriction site for MspI, and restriction digestion of PCR amplified genomic DNA demonstrated that all the patients were heterozygous for their mutations (Fig. 3A, B) .
The causal relationship between the reported mutations and HT1 was proven by expression analysis. The FAH activity in the translation mixture of positive control pALTER-1 with FAH insert (pALTER-1-FAH) was 37 gmol of fumarylacetoacetate hydrolysed per minute per liter, and the activity was, by serial dilution, linear to approximately 10%. No enzyme activity was detectable in the translation mixtures of pALTER-1-FAH with either the A134D or P342L mutation inserted. The negative controls, vector without insert, lane 6, or no DNA added, lane 7, gave no bands. The A134D and the P342L mutations were not found in ten additional chronic and two acute patients investigated. 
Discussion
We here report two different mutations causing chronic HT1. An A134D mutation is common for one Turkish and two Norwegian patients. Another missense mutation, P342L, was found in another Norwegian patient. All patients were demonstrated to be heterozygous for their respective mutation by restriction digestion of PCR amplified genomic DNA. Direct sequencing of amplified cDNA only detected the mutated allele. This might be explained by lack of transcription, unstable mRNA or unfavorable reverse transcription or PCR of the other allele. Since Northern blotting of the four patients demonstrated FAH mRNA of normal size and no striking reduction in quantity, the mutations here reported appear to be normally transcribed and the mRNA seems to be reasonably stable. The FAH immunoreactivity in fibroblasts from the three patients with A134D was less than the control. Assuming normal mRNA quantities and translation, the fact that in vitro translation of this mutation also gave less FAH protein than the normal sequence, measured by incorporated [35S]methionine, indicates a reduced stability rather than altered antigenic properties.
Immunoblots of the patient with the P342L mutation did not show immunoreactive material even after overexposure, but a weak band of the correct size was present after in vitro translation of the P342L mutation. This could be explained by a more rapid degradation of an unstable FAH protein in vivo than in the test tube, or by the higher detection sensitivity obtained using isotope incorporation. Another possible explanation is that the mutation alters a major epitope for antibody binding, although the polyclonal antibody presumably would detect a number of epitopes in the protein. Homology between human and bovine FAH is not known, but rat and murine FAH show approximately 90% amino acid homology with human FAH Grompe and A1-Dhalimy 1992) .
In the majority of chronic patients investigated, the A134D or P342L mutations were not detected, indicating several causal mutations in chronic HT1. This genetic variability may be part of the explanation for the clinical heterogeneity.
The three Norwegian patients, together demonstrating both reported mutations, all had variable FAH activity in liver tissue indicating mosaicism. If the correction of the FAH activity in some sections of the liver tissue is related to the primary genetic defect, elucidation of the causal mutations in patients with this phenomenon may be of particular interest. At present it is not clear whether the mutations reported here are related to the mosaicism phenomenon. Work is in progress to clarify a possible relationship.
quencing and for useful discussions and to Dr. Don W. Cleveland for the donation of the ~-actin cDNA.
